Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

PKM2 is not required for colon cancer initiated by APC loss.

Lau AN, Israelsen WJ, Roper J, Sinnamon MJ, Georgeon L, Dayton TL, Hillis AL, Yilmaz OH, Di Vizio D, Hung KE, Vander Heiden MG.

Cancer Metab. 2017 Nov 30;5:10. doi: 10.1186/s40170-017-0172-1. eCollection 2017.

2.

Bispentafluorophenyl-Containing Additive: Enhancing Efficiency and Morphological Stability of Polymer Solar Cells via Hand-Grabbing-Like Supramolecular Pentafluorophenyl-Fullerene Interactions.

Hung KE, Tsai CE, Chang SL, Lai YY, Jeng US, Cao FY, Hsu CS, Su CJ, Cheng YJ.

ACS Appl Mater Interfaces. 2017 Dec 20;9(50):43861-43870. doi: 10.1021/acsami.7b13426. Epub 2017 Dec 11.

PMID:
29165989
3.

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.

Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.

PMID:
25389372
4.

Overview of genetically engineered mouse models of colorectal carcinoma to enable translational biology and drug development.

Roper J, Martin ES, Hung KE.

Curr Protoc Pharmacol. 2014 Jun 16;65:14.29.1-10. doi: 10.1002/0471141755.ph1429s65.

PMID:
24934606
5.

Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.

Li X, Nadauld L, Ootani A, Corney DC, Pai RK, Gevaert O, Cantrell MA, Rack PG, Neal JT, Chan CW, Yeung T, Gong X, Yuan J, Wilhelmy J, Robine S, Attardi LD, Plevritis SK, Hung KE, Chen CZ, Ji HP, Kuo CJ.

Nat Med. 2014 Jul;20(7):769-77. doi: 10.1038/nm.3585. Epub 2014 May 25.

6.

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.

Belmont PJ, Budinska E, Jiang P, Sinnamon MJ, Coffee E, Roper J, Xie T, Rejto PA, Derkits S, Sansom OJ, Delorenzi M, Tejpar S, Hung KE, Martin ES.

Dis Model Mech. 2014 Jun;7(6):613-23. doi: 10.1242/dmm.013904. Epub 2014 Apr 17.

7.

Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras.

Byun AJ, Hung KE, Fleet JC, Bronson RT, Mason JB, Garcia PE, Crott JW.

Cancer Lett. 2014 Jun 1;347(2):191-5. doi: 10.1016/j.canlet.2014.03.004. Epub 2014 Mar 14.

8.

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.

Roper J, Sinnamon MJ, Coffee EM, Belmont P, Keung L, Georgeon-Richard L, Wang WV, Faber AC, Yun J, Yilmaz ÖH, Bronson RT, Martin ES, Tsichlis PN, Hung KE.

Cancer Lett. 2014 Jun 1;347(2):204-11. doi: 10.1016/j.canlet.2014.02.018. Epub 2014 Feb 24.

9.

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.

Cancer Discov. 2014 Jan;4(1):42-52. doi: 10.1158/2159-8290.CD-13-0315. Epub 2013 Oct 25.

10.

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.

Clin Cancer Res. 2013 May 15;19(10):2688-98. doi: 10.1158/1078-0432.CCR-12-2556. Epub 2013 Apr 2. Erratum in: Clin Cancer Res. 2013 Jul 15;19(14):4018.

11.

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, Goel G, Ji X, Xie Z, Xie T, Lamb J, Weinrich SL, VanArsdale T, Bronson RT, Xavier RJ, Vander Heiden MG, Kan JL, Mahmood U, Hung KE.

Clin Cancer Res. 2013 Jun 1;19(11):2929-40. doi: 10.1158/1078-0432.CCR-12-2307. Epub 2013 Feb 12.

12.

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA.

Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012 Dec 13.

13.

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.

Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M.

Nature. 2012 Nov 8;491(7423):254-8. doi: 10.1038/nature11465.

14.

In vivo optical molecular imaging of matrix metalloproteinase activity following celecoxib therapy for colorectal cancer.

Sheth RA, Kunin A, Stangenberg L, Sinnamon M, Hung KE, Kucherlapati R, Mahmood U.

Mol Imaging. 2012 Sep-Oct;11(5):417-25.

15.

Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.

Roper J, Hung KE.

Trends Pharmacol Sci. 2012 Aug;33(8):449-55. doi: 10.1016/j.tips.2012.05.001. Epub 2012 Jun 26. Review.

PMID:
22739258
16.

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA.

Cancer Discov. 2012 Mar;2(3):227-35. doi: 10.1158/2159-8290.CD-11-0341. Epub 2012 Jan 16.

17.

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, Sinnamon MJ, Lee L, Chen PC, Bronson RT, Martin ES, Hung KE.

PLoS One. 2011;6(9):e25132. doi: 10.1371/journal.pone.0025132. Epub 2011 Sep 26.

18.

Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia.

Chan AT, Baba Y, Shima K, Nosho K, Chung DC, Hung KE, Mahmood U, Madden K, Poss K, Ranieri A, Shue D, Kucherlapati R, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2777-85. doi: 10.1158/1055-9965.EPI-10-0529. Epub 2010 Sep 10.

19.

In vivo wide-area cellular imaging by side-view endomicroscopy.

Kim P, Chung E, Yamashita H, Hung KE, Mizoguchi A, Kucherlapati R, Fukumura D, Jain RK, Yun SH.

Nat Methods. 2010 Apr;7(4):303-5. doi: 10.1038/nmeth.1440. Epub 2010 Mar 14.

20.

Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.

Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U, Kucherlapati R.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1565-70. doi: 10.1073/pnas.0908682107. Epub 2010 Jan 4.

21.

Proteomic approaches to cancer biomarkers.

Hung KE, Yu KH.

Gastroenterology. 2010 Jan;138(1):46-51.e1. doi: 10.1053/j.gastro.2009.11.020. Epub 2009 Nov 17. Review. No abstract available.

22.

Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis.

Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, Forrester S, Porter A, Kunin A, Mahmood U, Haab BB, Hanash SM, Kucherlapati R.

Cancer Prev Res (Phila). 2009 Mar;2(3):224-33. doi: 10.1158/1940-6207.CAPR-08-0153. Epub 2009 Feb 24.

23.

A mouse plasma peptide atlas as a resource for disease proteomics.

Zhang Q, Menon R, Deutsch EW, Pitteri SJ, Faca VM, Wang H, Newcomb LF, Depinho RA, Bardeesy N, Dinulescu D, Hung KE, Kucherlapati R, Jacks T, Politi K, Aebersold R, Omenn GS, States DJ, Hanash SM.

Genome Biol. 2008;9(6):R93. doi: 10.1186/gb-2008-9-6-r93. Epub 2008 Jun 3.

24.

New road map through the land of IBD.

Hung KE.

Inflamm Bowel Dis. 2008 Jun;14(6):868-9. doi: 10.1002/ibd.20394. No abstract available.

PMID:
18275075
25.
26.

Mass spectrometry-based study of the plasma proteome in a mouse intestinal tumor model.

Hung KE, Kho AT, Sarracino D, Richard LG, Krastins B, Forrester S, Haab BB, Kohane IS, Kucherlapati R.

J Proteome Res. 2006 Aug;5(8):1866-78.

PMID:
16889408
27.

Colorectal cancer screening: today and tomorrow.

Hung KE, Chung DC.

South Med J. 2006 Mar;99(3):240-6; quiz 247-9. Review.

PMID:
16553098
28.

New insights into the molecular pathogenesis of colorectal cancer.

Hung KE, Chung DC.

Drug Discov Today Dis Mech. 2006 Winter;3(4):439.

29.

Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systematic review and meta-analysis of screening colonoscopy.

Lewis JD, Ng K, Hung KE, Bilker WB, Berlin JA, Brensinger C, Rustgi AK.

Arch Intern Med. 2003 Feb 24;163(4):413-20. Review.

PMID:
12588199

Supplemental Content

Support Center